Biotech Values

[DewDiligence]

NTMD is down 90% in the past
13 months and 33% in the past
two days. BiDil, which analysts
once predicted would sell half a
billion dollars a year, is selling
at an annual rate of $10*million*.

http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20060803:MTFH08861_2...

>>
NitroMed withdraws 2006 sales outlook; shares fall

Aug 3 (Reuters) - NitroMed Inc. <NTMD> on Thursday said it was withdrawing its sales forecast for 2006 as it was unable to quantify the impact of second-quarter achievements on the prescription growth of its heart failure drug BiDil.

Product sales of BiDil, which was launched in July 2005, accounted for all of the company's revenue during the first half of 2006.

The drugmaker had forecast sales of $20 million for 2006. Product sales in the first six months of 2006 were $5.2 million, NitroMed said in a statement.
<<